Search - tctmd.com

Displaying 1 - 16 of 16

Sort: Relevancy | Date

News Daily News

Year in Review: Top Prevention Stories of 2025

Michael O'Riordan

December 24, 2025

News Opinion CV Team Dispatch

December 2025 Dispatch for the CV Team

L.A. McKeown

December 23, 2025

News Daily News

SURPASS-CVOT Published: Large Trial Confirms CVD Efficacy of Tirzepatide

Michael O'Riordan

December 18, 2025

News Opinion Editor's Corner AHA 2025

What’s Going to Be Hot at AHA 2025?

Michael O'Riordan

November 05, 2025

News Opinion Editor's Corner

TCTMD's Top 10 Most Popular Stories for August 2025

Caitlin E. Cox

August 28, 2025

News Daily News

Tirzepatide Matches Dulaglutide in Large CV Outcomes Trial: SURPASS-CVOT

Michael O'Riordan

July 31, 2025

News Daily News

Tirzepatide Bests Semaglutide for Weight Loss: SURMOUNT-5 Top-line Results

Michael O'Riordan

December 04, 2024

News Daily News

Tirzepatide Provides Sustained BP Reduction in Overweight Adults

Todd Neale

August 15, 2024

News Daily News

Stopping Tirzepatide Leads to Rebound in Weight, Cardiometabolic Risk

Todd Neale

December 12, 2023

News Daily News

‘Stronger’ Evidence That High Lp(a) Concentrations Cause CVD

Yael L. Maxwell

December 12, 2019

News CV Team Pro

The Providence St. Vincent Medical Center Cath Lab Team

L.A. McKeown

September 12, 2019

News Industry News

Terumo Cardiovascular Group and Talis Clinical Introduce ACG-Perfusion™ and ACG-RemoteView™ Systems, Enhancing Efficiency of Clinical Care Team

May 07, 2019

Presentation LINC 2019

How I Do It: Venous Stenting for Chronic Venous Obstruction (CVO)

Presenter: Angela A. Kokkosis

January 25, 2019

Presentation CDM 2018

Cardiovascular Outcomes Trials (CVOT): Latest Results and Recommendations

Presenter: Dailey George

October 12, 2018

News Industry News

Intarcia Announces Successful Cardiovascular Safety Results in Phase 3 FREEDOM-CVO Trial for ITCA 650, an Investigational Therapy for Type 2 Diabetes

May 06, 2016

News Industry News

Takeda Presents Additional Data from Alogliptin's EXAMINE Cardiovascular Safety Outcomes Trial at the American Diabetes Association's 75th Scientific Sessions

June 05, 2015

Advertisement

Year in Review: Top Prevention Stories of 2025

December 2025 Dispatch for the CV Team

SURPASS-CVOT Published: Large Trial Confirms CVD Efficacy of Tirzepatide

What’s Going to Be Hot at AHA 2025?

TCTMD's Top 10 Most Popular Stories for August 2025

Tirzepatide Matches Dulaglutide in Large CV Outcomes Trial: SURPASS-CVOT

Tirzepatide Bests Semaglutide for Weight Loss: SURMOUNT-5 Top-line Results

Tirzepatide Provides Sustained BP Reduction in Overweight Adults

Stopping Tirzepatide Leads to Rebound in Weight, Cardiometabolic Risk

‘Stronger’ Evidence That High Lp(a) Concentrations Cause CVD

The Providence St. Vincent Medical Center Cath Lab Team

Terumo Cardiovascular Group and Talis Clinical Introduce ACG-Perfusion™ and ACG-RemoteView™ Systems, Enhancing Efficiency of Clinical Care Team

How I Do It: Venous Stenting for Chronic Venous Obstruction (CVO)

Cardiovascular Outcomes Trials (CVOT): Latest Results and Recommendations

Intarcia Announces Successful Cardiovascular Safety Results in Phase 3 FREEDOM-CVO Trial for ITCA 650, an Investigational Therapy for Type 2 Diabetes

Takeda Presents Additional Data from Alogliptin's EXAMINE Cardiovascular Safety Outcomes Trial at the American Diabetes Association's 75th Scientific Sessions

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content